May 4 (Reuters) - Moderna Inc on Wednesday maintained the full-year sales forecast for its COVID-19 vaccine at $21 billion, as cases fall and demand slackens after countries rushed to secure shots last year. (Reporting by Manas Mishra in Bengaluru; Editing by Saumyadeb Chakrabarty)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
111.6 USD | +3.38% | +6.85% | +12.24% |
29/04 | Wall Street: buoyed by Tesla, confident ahead of FOMC meeting | CF |
29/04 | Moderna Signs Nonexclusive License Deal in Japan for COVID-19-related Intellectual Property | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.24% | 41.34B | |
+1.77% | 42.75B | |
+47.70% | 41.61B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B | |
-16.39% | 10.07B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Moderna keeps full-year COVID vaccine sales view unchanged